Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

ByThe Short Paper

This study explored a treatment combination (obinutuzumab, ibrutinib, and venetoclax) for a specific type of leukemia (chronic lymphocytic leukemia with del(17p) and/or TP53 mutation) in previously untreated patients. The treatment involved several cycles and aimed to achieve complete remission. The results showed that 58.5% of patients achieved complete remission, and after around 3 years, the…

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

ByThe Short Paper

This study tested a new treatment called mezigdomide, combined with dexamethasone, for people with multiple myeloma (a type of cancer). The treatment showed promise in patients who had already tried other treatments, including those resistant to lenalidomide and pomalidomide. In the first phase of the study, they tested the treatment on 77 patients to determine…